Generic diabetes pill put to the test: will it match the brand?

NCT ID NCT07679711

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This trial tests whether a new generic extended-release tablet containing sitagliptin and metformin works the same in the body as the brand-name version (Janumet XR). Healthy Chinese adults receive a single dose of each tablet, separated by a washout period, under both fasting and fed conditions. Blood samples are taken to measure drug levels and check for safety. The goal is to see if the generic can be considered a suitable substitute for the brand.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sitagliptin/Metformin hydrochloride extended-release tablet
What this could lead to
If the test tablet proves equivalent to the reference, it could offer a more affordable generic option for managing type 2 diabetes.
What could go wrong
This is an early-phase bioequivalence study in healthy volunteers, not patients. Results may not predict real-world effectiveness or safety in people with diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, 266000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.